These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 3933283

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients.
    Streifler M, Rabey MJ.
    J Neural Transm Suppl; 1983; 19():265-72. PubMed ID: 6421992
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
    Przuntek H, Kuhn W.
    J Neural Transm Suppl; 1987; 25():97-104. PubMed ID: 3123607
    [Abstract] [Full Text] [Related]

  • 9. [Evaluation of the effectiveness of combined (L-dopa + Jumex) therapy based on a multicentric double blind study].
    Tariska I, Gallai M.
    Orv Hetil; 1983 Sep 18; 124(38):2309-14. PubMed ID: 6415577
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T, Yahr MD.
    Ann Neurol; 1995 Jan 18; 37(1):95-8. PubMed ID: 7818264
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [The use of L-deprenyl in Parkinson's disease].
    Zhonghua Yi Xue Za Zhi; 1983 Mar 18; 63(3):147-9. PubMed ID: 6409375
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Observations made with L-deprenil (Jumex) in the long-term treatment of outpatients with Parkinson's syndrome.
    Gyimóti G, Csanaky A, Leposa D.
    Ther Hung; 1983 Mar 18; 31(1):26-30. PubMed ID: 6443750
    [No Abstract] [Full Text] [Related]

  • 17. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y, Kondo T, Takubo H, Yokochi F.
    No To Shinkei; 1994 May 18; 46(5):465-71. PubMed ID: 8060685
    [Abstract] [Full Text] [Related]

  • 18. Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease.
    Birkmayer W, Riederer P.
    Adv Neurol; 1984 May 18; 40():475-81. PubMed ID: 6421111
    [No Abstract] [Full Text] [Related]

  • 19. (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
    Birkmayer W, Knoll J, Riederer P, Youdim MB.
    Mod Probl Pharmacopsychiatry; 1983 May 18; 19():170-6. PubMed ID: 6408405
    [No Abstract] [Full Text] [Related]

  • 20. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y, Kondo T, Takubo H, Yokochi F.
    No To Shinkei; 1996 May 18; 48(5):467-72. PubMed ID: 8672306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.